Brian Kearney, PharmD


Brian is a veteran of antiviral drug development with primary contributions leading to the approval of more than 15 new drugs. In a 20+ year career at Gilead Sciences, Inc., Brian built and led the clinical pharmacology and clinical development efforts from inception through global registrations and approvals for the treatment of HIV, HBV, HCV, and other unmet medical needs. Subsequently, Brian joined as a member of the founding management team of Pardes Biosciences, Inc, formed at the inception of the COVID-19 pandemic that advanced a potential oral therapy for SARS-CoV-2 infection from discovery through Phase 2 testing in less than three years.